Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysisImmune-related AEsNon-small cell lung cancerNivolumabImmune-checkpoint inhibitors (ICIs) represent the standard of care ...
In Reply We thank Cheng and colleagues for their interest in our study on the association of immune-related adverse events (irAEs) with nivolumab
据报道,与正常BMI相比,肥胖患者使用免疫检查点抑制剂可提高生存率。肥胖与免疫检查点抑制剂的安全性值得研究。 OBJECTIVE 目的 To investigate associations between BMI and immune-related adverse events (irAEs) among patients with advanced cancers treated with nivolumab monotherapy and nivolumab plus ipilimumab co...
This medical record review evaluates the relation of immune-related adverse events to nivolumab efficacy in non–small-cell lung cancer.
sometimes cause reactions in the immune system. these side effects may be called immune-mediated adverse events . they are relatively common and generally respond well to treatment. managing side effects patients may experience side effects while receiving opdivo and yervoy. but doctors have established...
Among the neurological complications described, exacerbation or de novo onset of myasthenia gravis are the most frequent immune-related adverse events, representing up to 0.1% of all severe adverse reactions to ICIs.6, 8, 9 Myasthenia gravis associated with ICIs seems to be more severe and to ...
Importance: Immune-related adverse events (irAEs) have been associated with the efficacy of PD-1 (programmed cell death protein 1) inhibitors in patients with melanoma, but whether such an association exists for non-small-cell lung cancer (NSCLC) has remained unknown. Objective: To evaluate the...
OS and PFS were also examined according to whether immune-related adverse events (irAEs) appeared. Statistical analysis was conducted using log-rank testing, with values of pResults: Nivolumab was administered to 100 patients with a history of receiving platinum-based drugs. ORR was 13.5% and ...
Immune-related AEs of all grades occurred in 46% of patients, including grades 3/4 AEs in 6% of participants. There were three deaths associated with pneumonitis early in the trial, resulting in the development of treatment algorithms for early detection and management, said Topalian. Reference ...
The ORR increased to 44%, with a median OS of 10.5 months, although a greater number of immune-related adverse events were associated with the treatment [94]. Another clinical trial is currently underway to obtain the promising data. The BCL-2 inhibitor venetoclax, administered in combination ...